Search Results

You are looking at 1 - 1 of 1 items for

  • Author: P Gonzalez-Saenz x
Clear All Modify Search
Free access

C Folgueira, S Barja-Fernandez, P Gonzalez-Saenz, V Pena-Leon, C Castelao, M Ruiz-Piñon, F F Casanueva, R Nogueiras and L M Seoane

Uroguanylin (UGN) is a potential target in the fight against obesity. The mature protein is released after enzymatic cleavage from its natural precursor, proUGN. UGN is mostly produced in the gut, and its production is regulated by nutritional status. However, UGN is also produced in other tissues such as the kidneys. In the past, UGN has been widely studied as a natriuretic peptide owing to its involvement in several different pathologies such as heart failure, cancer and gastrointestinal diseases. However, recent studies have suggested that UGN also acts as a regulator of body weight homeostasis because it modulates both food intake and energy expenditure. This ultimately results in a decrease in body weight. This action is mediated by the sympathetic nervous system. Future studies should be directed at the potential effects of UGN agonists in regulating body weight in human obesity.